# Gagandeep Kang (1962)

> Microbiologa indiana, prima donna indiana FRS, "Vaccine Godmother of India"

## Dati Essenziali

| Aspetto | Dettaglio |
|---------|-----------|
| **Nascita** | 3 novembre 1962, Shimla, India |
| **Nazionalita'** | India |
| **Background** | Padre ingegnere meccanico (Indian Railways), madre insegnante |

---

## Formazione

| Periodo | Istituzione | Dettaglio |
|---------|-------------|-----------|
| **1987** | [CMC Vellore](../university/cmc-vellore.md) | MBBS |
| **1991** | [CMC Vellore](../university/cmc-vellore.md) | MD Microbiology |
| **1998** | [CMC Vellore](../university/cmc-vellore.md) | PhD |
| **2000** | Royal College of Pathologists | Membership |
| **~2000** | [Baylor College of Medicine](../university/baylor-college-medicine.md) | Postdoc (con Mary K. Estes) |

---

## Carriera e Ruoli

### Timeline Professionale

| Periodo | Ruolo | Organizzazione |
|---------|-------|----------------|
| **1991-2023** | Faculty â†’ Senior Professor GI Sciences | [CMC Vellore](../university/cmc-vellore.md) |
| **2011-** | Principal Investigator Rotavac | [Bharat Biotech](../pharma/bharat-biotech.md) |
| **2016-2020** | Executive Director | [THSTI Faridabad](../agency/thsti.md) |
| **2018-2023** | Board member | [CEPI](../agency/cepi.md) |
| **2023-** | Director Enteric Diseases | [Gates Foundation](../foundation/gates-foundation.md) |

### Riconoscimenti

| Anno | Premio/Riconoscimento |
|------|----------------------|
| **2016** | Infosys Prize for Life Sciences |
| **2019** | Fellow of the Royal Society (FRS) - prima donna indiana |
| **2019** | Prima donna indiana FRS in 359 anni di storia |

---

## Rete di Connessioni

### Mappa delle Appartenenze

```
                    KANG
                      |
      +---------------+---------------+
      |               |               |
      v               v               v
Gates Foundation    CEPI          Royal Society
  (2023-)        (2018-2023)        (FRS 2019)
      |
      +-- Director Enteric & Diarrheal Diseases
```

### Advisory Roles

| Organizzazione | Ruolo |
|----------------|-------|
| **[WHO](../agency/who.md)** | Global Advisory Committee on Vaccine Safety |
| **[WHO](../agency/who.md)** | ITAG Chair South East Asia Region |
| **[WHO](../agency/who.md)** | COVID-19 Vaccine Safety Working Group |
| **NTAGI India** | COVID-19 Vaccine Working Group |

### Network Professionale

| Nome | Connessione |
|------|-------------|
| [Chris Elias](chris-elias.md) | Collega Gates Foundation |
| [Anita Zaidi](anita-zaidi.md) | Collega Gates Foundation |
| Mary K. Estes | Mentor postdoc Baylor |

---

## Potere Esercitato

### Vaccine Development

| Aspetto | Dettaglio |
|---------|-----------|
| **Rotavac** | Principal Investigator Phase III trials, vaccino WHO pre-qualified |
| **Impatto** | Vaccino riduce diarrea da rotavirus del 56% nel primo anno di vita |
| **Network** | Ha costruito reti nazionali di sorveglianza rotavirus e tifo |

### Global Health Governance

Kang rappresenta l'ascesa della scienza indiana nella governance sanitaria globale. Il suo passaggio da CMC Vellore a Gates Foundation segna il riconoscimento internazionale dell'expertise indiana nei vaccini.

---

## Pubblicazioni e Impatto

- **450+** pubblicazioni scientifiche
- Prima indiana e prima donna a editare Manson's Textbook of Tropical Medicine
- Membro editorial board di numerose riviste

---

## Connessioni PowerLink

### Organizzazioni

| Entita' | Connessione |
|---------|-------------|
| [Gates Foundation](../foundation/gates-foundation.md) | Director (2023-) |
| [CEPI](../agency/cepi.md) | Board member (2018-2023) |
| [WHO](../agency/who.md) | Advisor, ITAG Chair SE Asia |
| [CMC Vellore](../university/cmc-vellore.md) | Faculty (1991-2023) |
| [THSTI](../agency/thsti.md) | Executive Director (2016-2020) |
| [Bharat Biotech](../pharma/bharat-biotech.md) | PI Rotavac trials (2011-) |
| [Royal Society](../agency/royal-society.md) | FRS (2019-) |

### Persone

| Persona | Relazione |
|---------|-----------|
| [Chris Elias](chris-elias.md) | Collega Gates Foundation |
| [Anita Zaidi](anita-zaidi.md) | Collega Gates Foundation |

---

## Timeline

| Anno | Evento |
|------|--------|
| **1962** | Nasce a Shimla |
| **1987** | MBBS CMC Vellore |
| **1991** | MD Microbiology, inizia come faculty CMC |
| **1998** | PhD CMC Vellore |
| **~2000** | Postdoc Baylor con Mary K. Estes |
| **2011** | Inizia trial Phase III Rotavac |
| **2014** | Rotavac approvato in India |
| **2016** | Executive Director THSTI |
| **2016** | Infosys Prize for Life Sciences |
| **2018** | Board member CEPI |
| **2019** | Fellow Royal Society (prima donna indiana) |
| **2023** | Entra in Gates Foundation come Director |

---

## Fonti

### Biografie
- [Wikipedia - Gagandeep Kang](https://en.wikipedia.org/wiki/Gagandeep_Kang)
- [Royal Society - Professor Gagandeep Kang FRS](https://www.royalsociety.org/people/gagandeep-kang-14102/)

### Istituzioni
- [Gates Foundation - Leadership](https://www.gatesfoundation.org/about/leadership/gagandeep-kang)
- [Infosys Prize 2016](https://www.infosysprize.org/laureates/2016/gagandeep-kang.html)
- [WomenLift Health Profile](https://www.womenlifthealth.org/profile/gagandeep-kang/)

### Media
- [Nature - This Vaccine Godmother](https://pmc.ncbi.nlm.nih.gov/articles/PMC11506690/)

---

*Ultimo aggiornamento: Febbraio 2025*
